Skip to Main Content

Paper Details

Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer.
Cancer
1
2024
HGSOC, Patient, Patients, cytotoxic T-lymphocyte antigen 4, high-grade serous ovarian cancer, ovarian cancer, patient, patients, platinum, platinum-resistant ovarian cancer, programmed death ligand 1, tremelimumab
Author NameAffiliation
Anil K SoodThe University of Texas MD Anderson Cancer Center
Charlotte C SunThe University of Texas MD Anderson Cancer Center
  • 1 - 2

Datasets

Release 1.2